Status:
RECRUITING
Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
Lead Sponsor:
Hunan Province Tumor Hospital
Conditions:
Non Small Cell Lung Cancer
EGFR Gene Mutation
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to assess the Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation.
Detailed Description
The purpose of this study is to assess the Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation. Our study was set up with several group with EGFR mutant, ...
Eligibility Criteria
Inclusion
- Understand the requirements and contents of the clinical trial, and provide a signed and dated informed consent form.
- Age ≥ 18 years.
- Histologically or cytologically confirmed, Stage IV NSCLC.
- Oncogenic mutations confirmed by an accredited local laboratory, including EGFR, ALK, ROS1 etc.
- ECOG 0-1.
- Predicted survival ≥ 12 weeks.
- Adequate bone marrow hematopoiesis and organ function
- Presence of measurable lesions according to RECIST 1.1.
Exclusion
- The patient did not match from the Inclusion Criteria.
Key Trial Info
Start Date :
April 16 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 24 2027
Estimated Enrollment :
6000 Patients enrolled
Trial Details
Trial ID
NCT04322890
Start Date
April 16 2020
End Date
December 24 2027
Last Update
October 22 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yongchang Zhang
Changsha, Hunan, China, 410013